

S1 Fig. Power plots. Power for a) Baseline Lp-PLA2 activity in both placebo and darapladib arms (n=23,000) and Change from Baseline in darapladib arm (n = 11,500) at alpha = 5E-8; b) efficacy endpoints in both placebo and darapladib arms (n = 23,000) at alpha = 0.001 (candidate gene) and 5E-8 (GWAS) tolerability endpoints in darapladib arm only arms (n = 11,500) at alpha = 0.001 (candidate gene) and 5E-8 (GWAS).

